Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRVO with free AI briefings, catalyst countdowns, and dilution alerts.

CRVO · CervoMed Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$19.6M Cash on Hand
9.8mo Cash Runway
Follow CRVO by email Get an email when CRVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRVO, unsubscribe in one click. Privacy

📣 What CRVO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Neflamapimod Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Phase 2 · NCT07033481 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRVO holds $19.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $6M/quarter from operations, an estimated runway of 9.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRVO files for a raise →

👥 Who Owns CRVO

Insiders 23.4% Institutions 23.5% Public and other holders 53.1%
HolderTypeShares% of sharesAs of
Joshua S Boger
Director, 10% owner · +1.93M options
Insider 2,012,682 13.30% 2026-06-11
Armistice Capital, LLC Institution (13G, 5%+) 1,592,863 10.53% 2026-06-30
Sylvie Gregoire
Director, 10% owner · +151,250 options
Insider 1,496,578 9.89% 2025-11-17
John J Alam
CEO & President, Director, 10% owner · +91,250 options
Includes shares also reported by Sylvie Gregoire, counted once
Insider 1,496,578 9.89% 2025-11-17
RA Capital Management, L.P. Institution (13G, 5%+) 1,266,143 8.37% 2026-06-30
Woodline Partners LP Institution (13G, 5%+) 688,987 4.55% 2026-06-30
Matthew Winton
Chief Commercial and Business · +124,100 options
Insider 15,000 0.10% 2025-11-17
William Robert Elder
CFO, GC & Secretary · +57,000 options
Insider 12,500 0.08% 2025-11-17

Share count 15,128,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRVO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRVO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.